Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study

British Journal of Cancer

Volumn 86, Issue 2, 2002, Pages 207-212

  Grana, C ^a   Chinol, M ^a   Robertson, C ^a   Mazzetta, C ^a   Bartolomei, M ^a   De Cicco, C ^a   Fiorenza, M ^a   Gatti, M ^a   Caliceti, P ^b   Paganelli, G ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Avidin biotin; Glioma; Radioimmunotherapy

Indexed keywords

BIOTIN; YTTRIUM 90;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MALE; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AVIDIN; BIOTIN; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 18244367701     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600047     Document Type: Article

References (32)

1. Statistics notes. Treatment allocation in controlled trials: Why randomise?
2. The pharmacology of pretargeting components: Optimizing therapeutic targeting
3. Pathologic anatomy and CT correlations in the glioblastoma multiforme
4. Three-step radioimmunotherapy with yttrium-90-biotin: Dosimetry and pharmacokinetics in cancer patients
5. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
6. Selection bias, survival, and brachytherapy for glioma
7. Pharmacokinetics and antibodies
8. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens
9. Investigations of avidin and biotin for imaging applications
10. Imaging of tumour in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: Preliminary communication
11. Clinical radioimmunodetection., 1978-1988: Overview and suggestions for standardization of clinical trials
12. Radiation therapy for neoplasms of the brain
13. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma
14. National survey of patterns of care for brain-tumor patients
15. Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours
16. The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy
17. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin
18. 99mTc]PnAO- biotin
19. Three-step monoclonal antibody tumour targeting in carcinoembryonic antigen-positive patients
20. Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy
21. Intraperitoneal radiolocalization of tumors pre-targeted by biotinylated monoclonal antibodies
22. In vivo labelling of biotinylated monoclonal antibodies by radioactive avidin: A strategy to increase tumour radiolocalisation
23. Intralesional radioimmunotherapy of malignant gliomas: An effective treatment in recurrent tumors
24. Gene therapy for cancer: What have we done and where are we going?
25. High dose radiation therapy in the treatment of malignant gliomas: Final report
26. Epidemiology and factors affecting survival
27. Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding
28. Epidemiology of brain tumors: The national survey of intracranial neoplasms
29. The avidin-biotin complex in immunology
30. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracrianal malignancies